½ÉÀå µ¹¿¬»ç ¿¹¹æÀ» À§ÇÑ »ðÀÔÇü Á¦¼¼µ¿±âÀÇ ÀÓ»ó ¿¬±¸µé
Implantable cardioverter-defibrillator: clinical trial update
International Journal of Arrhythmia 2012³â 13±Ç 1È£ p.7 ~ p.12
À̸í¿ë(Lee Myung-Yong) - ´Ü±¹´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
Abstract
Implantable cardioverter-defibrillator (ICD) has been proved to be the most effective treatment strategy for primary and secondary prevention trials of sudden cardiac death and recurrence of symptomatic ventricular tachycardia, especially in patients with structural heart disease and a low LV ejection fraction. For patients who refuse to receive an ICD, empiric amiodarone therapy is considered as the next best treatment option, although many previous clinical studies have reported no reduction in the mortality rate with such empiric therapy. The usefulness of radiofrequency ablation for the prevention of sudden cardiac death is limited. This paper summarizes and reviews outstanding clinical trials that lead to the current concept of treatment strategy for the prevention of sudden cardiac death.
Å°¿öµå
implantable cardioverter-defibrillator, sudden cardiac death, clinical trial
KMID :
1011920120130010007
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
Instead of ICD, the usefulness of radiofrequency ablation for the prevention of sudden cardiac death is limited.